Source: Lynxbroker
Hard facts
In the last five years, turnover has increased massively from USD 11.4 billion to USD 15.4 billion.
At the same time, profitability has improved and the number of outstanding Aktien fell from 191 to 181 million units.
At the same time, earnings rose from USD 6.42 to USD 11.13 per share.
Nevertheless, IQVIA's share price has recently come under pressure. As the share had been treading water for a long time beforehand, the situation was already in a bad way from a technical point of view.
Added to this was the general selling pressure in the healthcare sector and fears of recession. Weak organic growth was also cited as a reason in the stock market media.
As is usual in such situations, there were several downgrades.
In the end, several important Unterstützungen were breached, which led to a veritable panic.
In my view, the fundamentals were completely ignored, as IQVIA has reported five times since the previous year's high and has exceeded expectations each time. Quartalszahlen and exceeded expectations each time. Although the share price has collapsed, earnings have risen by 9% to a record level of USD 11.13 per share in 2024.
Outlook and valuation
The positive development continued in the first quarter. At USD 2.70 per share, earnings were well above expectations of USD 2.62. With sales of USD 3.83 billion, the company also exceeded analysts' estimates of USD 3.76 billion.
For the year as a whole, this corresponds to a 3% increase in sales and a 6% jump in profits.
The growth momentum is certainly not spectacular, but this is not due to a lack of demand from customers, as the order backlog impressively demonstrates.
IQVIA is also assuming that the momentum will pick up again. Sales expectations for the current financial year have been raised from USD 15.7 - 16.1 billion to USD 16.0 - 16.4 billion.
Earnings are expected to rise by 5 - 9 % to USD 11.70 - 12.10 per share in the current financial year.
This makes it easy to justify a forward P/E of 13.9 in any sector, but even more so in this one. Since the merger of the two companies, IQVIA has never been valued lower than in the last few weeks.
Over the past five years, the P/E has averaged 23.
IQVIA share: chart from 14.07.2025, price: USD 162.80 - symbol: IQV | source: TWS
If the share now manages to rise above USD 168, a pro-cyclical upward trend Kaufsignalwith possible price targets at USD 180, 194 and 210.
If, on the other hand, the price falls below USD 155, the bulls will have lost their chance for the time being and a renewed setback to USD 137 must be expected.
complete article
